SCHEMBL20119916

SCHEMBL20119916

COCCOc1nc2c(NCc3ccncc3)nc(Cl)nc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 3/20 0.40
CDK2 P24941 3/20 0.40
CCNE2 O96020 2/20 0.40
PDE5A O76074 2/20 0.39
CDK1 P06493 3/20 0.38
PGK1 P00558 1/20 0.37
PDE10A Q9Y233 1/20 0.36
YTHDC1 Q96MU7 1/20 0.36
CTSL P07711 1/20 0.35
KDR P35968 4/20 0.35
FLT1 P17948 2/20 0.35
NT5E P21589 1/20 0.34
CNR1 P21554 1/20 0.34
APP P05067 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
CHRM4 P08173 1/20 0.34
CDK4 P11802 1/20 0.33
CCNB1 P14635 1/20 0.33
CCND1 P24385 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119867 0.94 CDK2 (0.40) CCNE1CDK2CCNE2PDE5ACDK1
SCHEMBL20119611 0.90 CDK1 (0.39) CCNE1CDK2CCNE2PDE5ACDK1
SCHEMBL20119503 0.89 CDK2 (0.40) CCNE1CDK2CCNE2PDE5ACDK1
SCHEMBL20119530 0.88 CDK1 (0.37) CCNE1CDK2CCNE2PDE5ACDK1
SCHEMBL20119522 0.87 CDK1 (0.40) CCNE1CDK2CCNE2PDE5ACDK1
SCHEMBL20119907 0.87 CCNE2 (0.44) CCNE1CDK2CCNE2PDE5ACDK1
SCHEMBL20120003 0.86 KCNH3 (0.34) CCNE1CDK2CCNE2CDK1CTSL
SCHEMBL20119728 0.82 CCNE2 (0.41) CCNE1CDK2CCNE2PDE5ACDK1
SCHEMBL20119546 0.82 CDK2 (0.36) CCNE1CDK2CCNE2PDE5ACDK1
SCHEMBL20119456 0.82 CDK1 (0.40) CCNE1CDK2CCNE2PDE5ACDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CCNE1 4220/4885CDK2 3622/4885CCNE2 4321/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 CCNE1 4220/4885CDK2 3622/4885CCNE2 4321/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CCNE1 4220/4885CDK2 3622/4885CCNE2 4321/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 CCNE1 4220/4885CDK2 3622/4885CCNE2 4321/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CCNE1 4220/4885CDK2 3622/4885CCNE2 4321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.